T. Carter

发表

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia

M. Caligiuri, C. Bloomfield, C. Croce, 2017, Proceedings of the National Academy of Sciences.

A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old

R. Larson, W. Stock, J. Kolitz, 2007 .

Successful non-surgical treatment of disseminated polymicrobial fungal infection in a patient with pancytopenia and graft-versus-host disease.

G. Selby, T. Carter, V. Roy, 2000, The Journal of infection.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Haematologica.

Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

M. Caligiuri, C. Bloomfield, K. Metzeler, 2012 .

A fatal case of West Nile virus infection in a bone marrow transplant recipient.

R. Gingrich, T. Carter, M. de Magalhaes-Silverman, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hypomethylating Agents and Low-Dose Venetoclax for Relapse Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation

C. Vigil, M. Silverman, T. Carter, 2020 .

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2014, Leukemia.

Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation

V. Roy, R. Mandanas, G. Selby, 2000, Anti-cancer drugs.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Pearlly Yan, Ralf Bundschuh, David Frankhouser, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Haematologica.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia

Guido Marcucci, Stefano Volinia, Andrew J. Carroll, 2014, Proceedings of the National Academy of Sciences.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Blood.

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Leukemia.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Guido Marcucci, Jessica Kohlschmidt, Heiko Becker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Guido Marcucci, Heiko Becker, Sebastian Schwind, 2010, Blood.

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Klaus H. Metzeler, Guido Marcucci, Stefano Volinia, 2013, Leukemia.

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8

M. Caligiuri, M. Radmacher, K. Metzeler, 2014, Leukemia.

A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

M. Tallman, G. Borthakur, D. DeAngelo, 2014, PloS one.

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Leukemia.

miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53

M. Caligiuri, C. Bloomfield, M. Radmacher, 2014 .